AB Akola group financials
AB Akola group
Country: LT Reporting currency: EUR Latest annual report: 2025-06-30
LEI:
529900UB9QON717IL030 Financial statements
(EUR, as reported — unscaled; 159 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Cost of sales | €1.39B | €1.36B |
| Gross profit | €194.1M | €151.1M |
| Other income | €8.4M | €10.2M |
| Operating profit (EBIT) | €78.9M | €46.1M |
| Finance costs | €22.7M | €24.5M |
| Profit before tax | €62.1M | €27.0M |
| Income tax expense | €1.4M | €2.1M |
| Profit for the year | €60.7M | €24.9M |
| — attributable to owners | €54.3M | €21.9M |
| — attributable to NCI | €6.4M | €3.0M |
| Total comprehensive income | €60.7M | €24.8M |
| Per share | ||
| Basic EPS | €0.36 | €0.15 |
| Diluted EPS | €0.36 | €0.15 |
| Free cash flow / share | €-0.07 | €0.31 |
| Cash flow statement | ||
| Net cash from operating activities | €46.3M | €93.7M |
| Income taxes paid | €1.7M | €0 |
| Net cash from investing activities | -€70.4M | -€46.5M |
| Net cash from financing activities | €21.8M | -€44.2M |
| Dividends paid | €5.0M | €4.2M |
| Proceeds from borrowings | €107.5M | €68.4M |
| Repayments of borrowings | €50.6M | €73.2M |
| Lease liability payments | €10.9M | €14.4M |
| Balance sheet | ||
| Total assets | €1.01B | €886.1M |
| Non-current assets | €345.9M | €288.6M |
| Property, plant & equipment | €241.3M | €205.6M |
| Right-of-use assets | €44.0M | €37.2M |
| Intangible assets & goodwill | €11.3M | €9.3M |
| Current assets | €668.4M | €597.5M |
| Inventories | €227.4M | €222.8M |
| Trade & other receivables | €347.6M | €295.8M |
| Cash & equivalents | €13.7M | €16.0M |
| Total equity | €368.2M | €312.3M |
| — attributable to owners | €344.7M | €295.6M |
| Non-controlling interests | €23.5M | €16.7M |
| Non-current liabilities | €148.8M | €108.0M |
| Lease liabilities (non-current) | €41.9M | €35.8M |
| Current liabilities | €497.2M | €465.7M |
| Current portion of long-term borrowings | €21.8M | €18.5M |
| Lease liabilities (current) | €10.7M | €14.9M |
| Trade & other payables | €172.1M | €185.2M |
| Deferred tax liabilities | €2.0M | €1.4M |
| Derived metrics | ||
| Free cash flow | -€11.5M | €51.7M |
| Operating margin | 5.0% | 3.1% |
| Net margin | 3.8% | 1.7% |
| Return on equity | 16.5% | 8.0% |
| Cash conversion ratio | 0.76× | 3.76× |
| Capex coverage | 0.80× | 2.23× |
| Other reported items | ||
| Additions To Rightofuse Assets | €14.3M | €16.6M |
| Adjustments For Decrease Increase In Accrued Income Including Contract Assets | -€812.0K | -€1.2M |
| Adjustments For Decrease Increase In Biological Assets | -€1.8M | €3.6M |
| Adjustments For Decrease Increase In Inventories | €14.2M | €46.5M |
| Adjustments For Decrease Increase In Loans and Advances To Customers | -€11.1M | -€4.9M |
| Adjustments For Decrease Increase In Other Assets | €0 | €377.0K |
| Adjustments For Decrease Increase In Other Operating Receivables | €472.0K | -€170.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -€38.4M | €4.4M |
| Adjustments For Deferred Tax Expense | -€3.7M | -€126.0K |
| Adjustments For Dividend Income | €0 | €0 |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | €0 | €0 |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €7.4M | €3.7M |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -€709.0K | -€2.4M |
| Adjustments For Impairment Loss Recognised In Profit Or Loss Goodwill | €2.2M | €0 |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | €472.0K | -€216.0K |
| Adjustments For Income Tax Expense | €3.3M | €2.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€18.1M | -€16.8M |
| Adjustments For Interest Expense | €22.7M | €24.5M |
| Adjustments For Interest Income | €6.4M | €5.4M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€1.3M | -€1.4M |
| Adjustments For Provisions | €0 | €30.0K |
| Adjustments For Sharebased Payments | €27.0K | €56.0K |
| Adjustments For Undistributed Profits of Associates | -€638.0K | €13.0K |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €354.0K | €0 |
| Cash Flows From Used In Operations Before Changes In Working Capital | €103.2M | €67.3M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €23.1M | €12.7M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €464.0K | €249.0K |
| Comprehensive Income Attributable To Noncontrolling Interests | €6.5M | €3.1M |
| Comprehensive Income Attributable To Owners of Parent | €54.3M | €21.8M |
| Current Biological Assets | €33.8M | €32.0M |
| Current Contract Assets | €9.2M | €5.7M |
| Current Contract Liabilities | €5.1M | €3.6M |
| Current Derivative Financial Assets | €970.0K | €1.6M |
| Current Derivative Financial Liabilities | €251.0K | €161.0K |
| Current Finance Lease Receivables | €0 | €0 |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | €24.4M | €10.5M |
| Current Tax Assets Current | €2.0M | €3.1M |
| Current Tax Liabilities Current | €2.6M | €179.0K |
| Decrease Increase Through Tax On Sharebased Payment Transactions | €568.0K | -€1.1M |
| Deferred Tax Assets | €12.7M | €8.4M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €396.0K | €1.4M |
| Dividends Received Classified As Investing Activities | €0 | €0 |
| Dividends Received Classified As Operating Activities | €0 | €0 |
| Dividends Recognised As Distributions To Noncontrolling Interests | €396.0K | €1.4M |
| Dividends Recognised As Distributions To Owners Per Share | €0.03 | €0.02 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€62.0K | €265.0K |
| Equity and Liabilities | €1.01B | €886.1M |
| Finance Income | €6.4M | €5.4M |
| General and Administrative Expense | €72.2M | €65.6M |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | €2.2M | -€145.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €2.1M | €6.2M |
| Increase Decrease In Allowance Account For Credit Losses of Financial Assets | -€2.2M | €145.0K |
| Increase Decrease In Cash and Cash Equivalents | -€2.2M | €3.0M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €0 | €0 |
| Increase Decrease Through Disposal of Subsidiary | €2.0K | -€205.0K |
| Increase Decrease Through Sharebased Payment Transactions | €27.0K | €56.0K |
| Increase Decrease Through Transactions With Owners | — | €0 |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | — | €0 |
| Increase Decrease Through Treasury Share Transactions | €0 | €0 |
| Interest Paid Classified As Financing Activities | €22.3M | €22.9M |
| Interest Received Classified As Investing Activities | €6.4M | €5.4M |
| Investment Property | €623.0K | €742.0K |
| Investments In Associates | €3.0M | €1.5M |
| Investments In Subsidiaries | €0 | €0 |
| Issued Capital | €48.5M | €48.5M |
| Noncontrolling Interest In Acquiree Recognised At Acquisition Date | -€9.0K | -€57.0K |
| Noncurrent Biological Assets | €24.3M | €16.4M |
| Noncurrent Finance Lease Receivables | €0 | €0 |
| Noncurrent Financial Assets | €8.8M | €9.3M |
| Noncurrent Government Grants | €11.3M | €8.4M |
| Noncurrent Payables | €11.0K | €1.0K |
| Noncurrent Prepayments | €471.0K | €828.0K |
| Noncurrent Provisions For Employee Benefits | €1.6M | €1.2M |
| Noncurrent Receivables | €7.5M | €7.1M |
| Noncurrent Receivables From Contracts With Customers | €194.0K | €1.4M |
| Other Adjustments To Reconcile Profit Loss | €0 | €0 |
| Other Comprehensive Income | €23.0K | -€66.0K |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €355.0K | €400.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €121.0K | €350.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €23.0K | -€66.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Current Financial Assets | €8.5M | €6.3M |
| Other Current Liabilities | €52.4M | €50.8M |
| Other Expense By Function | €5.9M | €7.1M |
| Other Financial Assets | €527.0K | €1.1M |
| Other Inflows Outflows of Cash Classified As Investing Activities | -€600.0K | €132.0K |
| Other Noncurrent Financial Assets | €20.0K | €61.0K |
| Other Noncurrent Liabilities | €1.4M | €1.2M |
| Other Noncurrent Nonfinancial Liabilities | €1.7M | €0 |
| Other Reserves | €8.5M | €4.8M |
| Other Shortterm Provisions | €3.4M | €3.7M |
| Payments From Changes In Ownership Interests In Subsidiaries | €9.0K | €58.0K |
| Prepayments | €600.0K | €0 |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €6.2M | €4.5M |
| Proceeds From Government Grants Classified As Financing Activities | €3.6M | €3.5M |
| Proceeds From Sales of Interests In Associates | €0 | €333.0K |
| Purchase of Interests In Associates | €0 | €1.4M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €57.8M | €42.1M |
| Reclassification Adjustments On Cash Flow Hedges Net of Tax | €453.0K | €816.0K |
| Reserve of Exchange Differences On Translation | €178.0K | €96.0K |
| Retained Earnings | €262.1M | €216.8M |
| Revenue From Contracts With Customers | €1.58B | €1.51B |
| Revenue From Dividends | €0 | €0 |
| Selling Expense | €43.3M | €42.7M |
| Selling General and Administrative Expense | €115.4M | €108.3M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€638.0K | €13.0K |
| Share Premium | €25.8M | €25.8M |
| Trade and Other Current Payables To Related Parties | €384.0K | €272.0K |
| Trade and Other Payables | €172.5M | €185.5M |
| Trade and Other Receivables Due From Related Parties | €8.0K | €2.4M |
| Treasury Shares | €344.0K | €411.0K |
Methodology
Every line item above is a fact tagged in AB Akola group's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.